CELC
CelcuityANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bullish view rests on the June 2 VIKTORIA-1 mutant-cohort result: the gedatolisib triplet beat the comparator on PFS, safety was described as manageable, and management says the FDA submission and commercial launch path remain on track [#8-K-2026-06-02] [#SEC-8K-2026-03-25]. The VIKTORIA-2 expansion and subcutaneous formulation work add longer-dated upside if the launch goes well.
Posture
Constructive
Lead driver
Momentum
What changed
1 setup hits (3d) with net bearish as of 2026-06-02.
What can break
Cash burn and expense ramp: the Q1 2026 update showed a $52.8M net loss and $55.1M in operating cash use, with R&D and SG&A both elevated as launch spending rises [#PR-EARNINGS-2026-05-15].
Momentum
84
Value
41
Sentiment
78
Setup hits (3d)
1 · Net Bearish
AI TargetsBase $114.00 · Bull $145.00 · Bear $68.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bearish
Target $116.70
Why
Momentum84 · Δ7d -3.2
Value41 · Δ7d +0.1
Sentiment78 · Δ7d +13.8
So what
Strength-led posture (Net Bearish). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
84
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.2
Δ21d
+0.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
78
33% active weight
Current posture
7d trendImproving
Δ7d
+13.8
Δ21d
+9.5
Why this grade
Composite grade A. Momentum 83.5 / Value 41.1 / Sentiment 77.8
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$6B
Beta
0.37
Shares Out
46.27M
P/E (TTM) · Derived
-45.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-39.62
Rev YoY
-
EPS YoY
-32.2%
Gross Margin
-
Op Margin
-
Net Debt
-$137.38M
Current Ratio
12.26
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology